Drug Trial Radar · NCT01698684
Research Evaluating a PDE5 Inhibitor for Erectile Dysfunction
Last checked: Nov 20, 2026Latest source record: Oct 27, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
440
Actual
Start
Sep 2012
Primary completion
Apr 2013
Study completion Apr 2013
Sponsor
- Lead sponsor
- VIVUS LLCIndustry
- Sponsor type
- Industry
- First posted
- Oct 3, 2012
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objectives of this study are to examine the therapeutic effects of two doses of avanafil after dosing in men with erectile dysfunction
Conditions
- Erectile Dysfunction
Interventions
PlaceboDrug
One dose 15 minutes before attempting intercourse
Avanafil 100 mgDrug
One dose 15 minutes before attempting intercourse
Avanafil 200 mgDrug
One dose 15 minutes before attempting intercourse
Primary outcomes
What the sponsor says the trial is designed to measure.
- Per-subject Proportion of Sexual Attempts That Had an Erectogenic Effect Within Approximately 15 Minutes Following DosingTime frame: Week 0 (Baseline) up to Week 8 (End of Study)
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Site not named
Jupiter, Florida
Site not named
Raleigh, North Carolina
Site not named
Wilmington, North Carolina
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.